{"id":743787,"date":"2013-05-22T17:28:00","date_gmt":"2013-05-22T17:28:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\/"},"modified":"2023-03-22T00:04:37","modified_gmt":"2023-03-22T04:04:37","slug":"merck-statement-on-fda-advisory-committee-meeting-for-suvorexant","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\/","title":{"rendered":"Merck Statement on FDA Advisory Committee Meeting for Suvorexant"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today provided the following statement after the conclusion of the<br \/>\n      Peripheral and Central Nervous System Drugs Advisory Committee meeting<br \/>\n      of the U.S. Food and Drug Administration (FDA) about suvorexant, Merck\u2019s<br \/>\n      investigational medicine to treat insomnia.\n    <\/p>\n<p>\n      \u201cWe are excited about the potential of suvorexant as a new and different<br \/>\n      approach to treating insomnia, a serious condition that affects up to<br \/>\n      one-third of the adult population,\u201d said Darryle Schoepp, Ph.D., senior<br \/>\n      vice president and head of Neuroscience and Ophthalmology, Merck<br \/>\n      Research Laboratories. \u201cToday\u2019s votes and discussion bring us one step<br \/>\n      closer to providing physicians with another option to help patients<br \/>\n      struggling with insomnia. We look forward to working with the FDA as the<br \/>\n      agency continues its review of our application.\u201d\n    <\/p>\n<p>\n      If approved, suvorexant would be the first in a new class of medicines,<br \/>\n      called orexin receptor antagonists, for use in patients with insomnia, a<br \/>\n      condition characterized by difficulty falling asleep and\/or staying<br \/>\n      asleep. Suvorexant\u2019s novel mechanism is distinct from current<br \/>\n      treatments. Merck researchers developed suvorexant to block the action<br \/>\n      of orexins, neurotransmitters in a specific part of the brain that help<br \/>\n      to keep a person awake. By temporarily blocking the actions of orexins,<br \/>\n      suvorexant helps to facilitate sleep.\n    <\/p>\n<p>\n      The FDA will consider the Committee\u2019s recommendations as it completes<br \/>\n      its review of the New Drug Application (NDA) for suvorexant. The FDA is<br \/>\n      not bound by the Committee\u2019s guidance, but takes its advice into<br \/>\n      consideration when reviewing investigational medicines. Merck<br \/>\n      anticipates FDA action on suvorexant in mid-year. If approved by the<br \/>\n      FDA, suvorexant will become available after a schedule assessment and<br \/>\n      determination has been completed by the U.S. Drug Enforcement<br \/>\n      Administration, which typically takes place after FDA approval.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&#038;esheet=50638869&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=1&#038;md5=7b4f4441096fe2a6878f2258c087af0d\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50638869&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=2&#038;md5=8507816a23442b197e50b81718b467cc\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20130522006730r1&#038;sid=sfsite1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 908-423-5042<br \/>or<br \/>Tracy        Ogden, 267-305-2301<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        908-423-4465<br \/>or<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided the following statement after the conclusion of the Peripheral and Central Nervous System Drugs Advisory Committee meeting of the U.S. Food and Drug Administration (FDA) about suvorexant, Merck\u2019s investigational medicine to treat insomnia. \u201cWe are excited about the potential of suvorexant as a new and different approach to treating insomnia, a serious condition that affects up to one-third of the adult population,\u201d said Darryle Schoepp, Ph.D., senior vice president and head of Neuroscience and Ophthalmology, Merck Research Laboratories. \u201cToday\u2019s votes and discussion bring us one step closer to providing physicians with another option to help patients struggling with insomnia. We look forward to working with the FDA as the agency continues its review of our application.\u201d If approved, suvorexant would be the first in a new class of medicines, called orexin receptor antagonists, for use in patients with<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-743787","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Statement on FDA Advisory Committee Meeting for Suvorexant - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Statement on FDA Advisory Committee Meeting for Suvorexant - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided the following statement after the conclusion of the Peripheral and Central Nervous System Drugs Advisory Committee meeting of the U.S. Food and Drug Administration (FDA) about suvorexant, Merck\u2019s investigational medicine to treat insomnia. \u201cWe are excited about the potential of suvorexant as a new and different approach to treating insomnia, a serious condition that affects up to one-third of the adult population,\u201d said Darryle Schoepp, Ph.D., senior vice president and head of Neuroscience and Ophthalmology, Merck Research Laboratories. \u201cToday\u2019s votes and discussion bring us one step closer to providing physicians with another option to help patients struggling with insomnia. We look forward to working with the FDA as the agency continues its review of our application.\u201d If approved, suvorexant would be the first in a new class of medicines, called orexin receptor antagonists, for use in patients with\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:37+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130522006730r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\\\/\",\"name\":\"Merck Statement on FDA Advisory Committee Meeting for Suvorexant - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130522006730r1&sid=sfsite1&distro=nx\",\"datePublished\":\"2013-05-22T17:28:00+00:00\",\"dateModified\":\"2023-03-22T04:04:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130522006730r1&sid=sfsite1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130522006730r1&sid=sfsite1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Statement on FDA Advisory Committee Meeting for Suvorexant\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Statement on FDA Advisory Committee Meeting for Suvorexant - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\/","og_locale":"en_US","og_type":"article","og_title":"Merck Statement on FDA Advisory Committee Meeting for Suvorexant - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided the following statement after the conclusion of the Peripheral and Central Nervous System Drugs Advisory Committee meeting of the U.S. Food and Drug Administration (FDA) about suvorexant, Merck\u2019s investigational medicine to treat insomnia. \u201cWe are excited about the potential of suvorexant as a new and different approach to treating insomnia, a serious condition that affects up to one-third of the adult population,\u201d said Darryle Schoepp, Ph.D., senior vice president and head of Neuroscience and Ophthalmology, Merck Research Laboratories. \u201cToday\u2019s votes and discussion bring us one step closer to providing physicians with another option to help patients struggling with insomnia. We look forward to working with the FDA as the agency continues its review of our application.\u201d If approved, suvorexant would be the first in a new class of medicines, called orexin receptor antagonists, for use in patients with","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:37+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130522006730r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\/","name":"Merck Statement on FDA Advisory Committee Meeting for Suvorexant - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130522006730r1&sid=sfsite1&distro=nx","datePublished":"2013-05-22T17:28:00+00:00","dateModified":"2023-03-22T04:04:37+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130522006730r1&sid=sfsite1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130522006730r1&sid=sfsite1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-suvorexant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Statement on FDA Advisory Committee Meeting for Suvorexant"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"dd5961ef-4362-491f-9565-be824f0a4a00","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743787\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=743787"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=743787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}